A substantial proportion of candidates for transcatheter aortic valve implantation (TAVI) still present a contraindication to transfemoral (TF) access. Furthermore, major vascular and bleeding complications remain concerning issues in patients undergoing TF TAVI, with an accompanying significant impact on mortality and morbidity.
Transcarotid (TC) TAVI was initially described by Modine et al1; it has subsequently proven to be reproducible2,3 and is associated with significant potential regarding early morbidity and hospital stay. Nonetheless, it still has not achieved broad consensus.
In this report, we sought to present a single-centre experience of TC TAVI, with particular focus ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com